Physician profile
Ryan P Johnson
NPI 1053970087
$2,010.55
in general payments reported to CMS, 2019-2025
28 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $525 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.23 | 2024-2025 | |
| Emd Serono, INC. | $216.80 | 2024-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $141.10 | 2024-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $116.39 | 2025 | Ponvory |
| Ucb, INC. | $100.46 | 2024-2025 | Rystiggo, Briviact |
| Eisai INC. | $99.71 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $87.82 | 2025 | Acthar |
| Lundbeck LLC | $78.00 | 2025 | Vyepti |
| Biogen, INC. | $65.78 | 2025 | Vumerity, Tysabri |
| Neurelis, INC. | $57.27 | 2025 | Valtoco |
| Grifols USA, LLC | $56.66 | 2024-2025 | Gamunex-C |
| Novartis Pharmaceuticals Corporation | $47.18 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $46.82 | 2024-2025 | Nuplazid |
| Axsome Therapeutics, INC. | $37.68 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $37.31 | 2024-2025 | Crexont |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $37.05 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Celgene Corporation | $34.19 | 2025 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $29.29 | 2025 | |
| Pfizer INC. | $27.25 | 2024 | |
| Janssen Biotech, INC. | $24.11 | 2025 | |
| Ani Pharmaceuticals, INC. | $19.66 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $19.63 | 2024 | Nourianz |
| Hospira, INC. | $18.44 | 2024 | |
| Argenx US, INC. | $17.68 | 2024 | Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $17.34 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.21 | 2024 | |
| Lilly USA, LLC | $16.56 | 2024 | Emgality |
| Sk Life Science, INC. | $13.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.